AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Progress in pneumococcal vaccine development reported.(Brief Article)
2002 OCT 2 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - A need exists for inexpensive pneumococcal vaccines that cover a broad serotype range, according to a review in the Scandinavian Journal of Immunology.
"Streptococcus pneumoniae is a leading cause of bacterial pneumonia, meningitis, and acute otitis media in children and adults worldwide," said T. Wuorimaa and H. Kayhty of the University of Helsinki. "The emergence of resistant strains necessitates the development of an effective vaccine with a large serotype coverage. "
Wuorimaa and Kayhty report that World Health Organization data reveal that each year pneumococcal pneumonia kills at least 1 million children younger than 5 years. Up to 83% of all serious pneumococcal illness is caused by the 11 most prevalent serotypes.
The vaccine offering the widest serotype coverage, the 23-valent pneumococcal polysaccharide vaccine, is low-cost but effective only in adults. In contrast, conjugate vaccines, such as the newly released 7-valent conjugate vaccine, are capable of generating a protective immune response in infants.
This new vaccine offers adequate protection in Europe ...
- 23-Valent pneumococcal revaccination offers short-term protection for elderly.
- Newspaper article from: TB & Outbreaks Week April 1, 2003 700+ words
...adults by revaccination with a 23-valent pneumococcal polysaccharide vaccine if given...who were revaccinated with a 23-valent pneumococcal polysaccharide vaccine 5 years after...who were revaccinated with a 23-valent pneumococcal polysaccharide vaccine 5 years after...
- Canadian researchers evaluate 7-valent pneumococcal conjugate vaccine.
- Newspaper article from: Vaccine Weekly March 19, 2003 700+ words
...NewsRx.net) -- A pharmacoeconomic evaluation of a 7-valent pneumococcal conjugate vaccine was conducted in Canada. "The objective...Infectious Diseases (A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada. Clin Infect Dis, 2003...
- Poor potential coverage for 7-valent pneumococcal conjugate vaccine, Malawi....
- Magazine article from: Emerging Infectious Diseases Gordon, Stephen B. Kanyanda, Stonard Walsh, Amanda L. Goddard, Kirsty Chaponda, Mas Atkinson, Victoria Mulwafu, Wakisa Molyneux, Elizabeth M. Zijlstra, Ed E. Molyneux, Malcolm E. Graham, Steve M. June 1, 2003 700+ words
...United States and Europe after the licensing of a 7-valent pneumococcal conjugate vaccine (3), and the Global Alliance for...uses a matrix to group pneumococci covered by the 23-valent pneumococcal vaccine but does not allow typing of pneumococci to the...
- Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal...
- Press release article from: PR Newswire May 29, 2008 700+ words
...Track designation to the Company's investigational 13-valent pneumococcal conjugate vaccine for infants and toddlers. Wyeth is...first quarter of 2009. Wyeth's investigational 13-valent pneumococcal conjugate vaccine is being studied in Phase 3 global clinical...
- Modern-Day Eugenics? Pneumonia Vaccine Targets Minorities.(selective use of...
- Magazine article from: Mothering May 1, 2000 700+ words
...receive this immunization. The vaccine, conjugated 7-valent pneumococcal vaccine, has never been properly tested for safety by...7192/1169 for further information.) Conjugated 7-valent pneumococcal vaccine is structurally similar to the meningitis (Hib...
- Fourth dose of PCV7 vaccine suspended due to shortage: supplies limited until...
- Magazine article from: Family Practice News Splete, Heidi March 1, 2004 700+ words
Due to limited supply of 7-valent pneumococcal conjugate vaccine, several major medical groups have...recommend suspending routine use of the fourth dose of 7-valent pneumococcal conjugate vaccine (PCV7 or Prevnar) after Wyeth Pharmaceuticals...
- Invasive pneumococcal disease in England and Wales: what is the true burden and...
- Magazine article from: Archives of Disease in Childhood McIntosh, E.D.G. Booy, R. June 1, 2002 700+ words
...may be at least three times the reported rate. The 7 valent pneumococcal conjugate vaccine may have the potential to prevent up...attributed definitely to pneumococcal infection. A 7 valent pneumococcal conjugate vaccine covering serotypes 4, 6B, 9V, 14...
- European Medicines Agency Decision of 20 Apr 2009 on the acceptance of a...
- News wire article from: Chemical Business Newsbase June 10, 2009 700+ words
...agreed Paediatric Investigation Plan for 13 valent pneumococcal polysaccharide conjugate vaccine. The...agreed Paediatric Investigation Plan for 13 valent pneumococcal polysaccharide conjugate vaccine were accepted...
- Cyprus and Ireland Add Wyeth's 7-Valent Pneumococcal Conjugate Vaccine (PCV7)...
- Press release article from: PR Newswire September 4, 2008 700+ words
...years of age worldwide.(3) The World Health Organization (WHO) recommends priority inclusion of the 7-valent pneumococcal conjugate vaccine in national childhood immunization programs worldwide due to the significant burden of pneumococcal...
- Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently...
- Press release article from: PR Newswire July 8, 2008 700+ words
...Microbiology, RWTH-Aachen, Germany. The World Health Organization (WHO) recommends priority inclusion of the 7-valent pneumococcal conjugate vaccine in national childhood immunization programs worldwide due to the significant burden of pneumococcal...
Source: HighBeam Research, Progress in pneumococcal vaccine development reported.(Brief Article)